

Global Market Report

Inside the Tech Wreck

Analyzing the Recent Sell-Off in Information Technology and Health Care
Using MSCI Indexes and GEM3

Zoltán Nagy and Jose Menchero

zoltan.nagy@msci.com

jose.menchero@msci.com

April 2014

*"The stock market's recent drop might not have been so unsettling to investors but for one thing: **the lack of a clear reason as to why it happened.**"*

Heard on the Street
Stock Sell-Off's Mystery Momentum
The Wall Street Journal
April 8, 2014

Introduction

Earlier this month, market observers were puzzled by the recent information technology and health care stock sell-off. But the granularity of the Barra Global Equity Model (GEM3) offers some solid answers.

During the first seven weeks of 2014, information technology and health care stocks performed notably well. By late February 2014, the global Pharmaceuticals & Biotechnology GICS industry group in the MSCI ACWI¹ Investable Market Index (IMI) had outperformed the global equity market by more than 800 bps. At the same time, the global Software & Services GICS industry group beat the global market by roughly 400 bps.

However, early March 2014 saw a reversal in this strong performance. In the six weeks from March 1 through April 10, the Pharmaceuticals & Biotechnology industry group gave back almost all of its gains, year-to-date. The Software & Services industry group fared even worse; year-to-date, it has underperformed the broad global equity market by more than 200 bps.

In this Global Market Report, we analyze the recent sell-off in information technology and health care stocks using MSCI Indexes and GEM3. First we look at the broad GICS sectors of Information Technology and Health Care, drilling down to those GICS industry groups hit hard by the recent drops: Software & Services and Pharmaceutical & Biotechnology.

GEM3 allows us to look inside the GICS industry groups and examine the drivers of this recent run-up and sell-off – not only industry factors but, importantly, style factors and stock-specific contributions.


¹ The MSCI All Country World Index (ACWI) covers approximately 14,000 securities and includes large, mid, small and micro cap size segments for all Developed Markets countries in the index together with large, mid and small cap size segments for the Emerging Markets countries.

Divergence in Industry Group Performance

We begin by examining the performance of industry groups within the Information Technology and Health Care sectors. We first consider the Health Care sector (GICS code 35), which consists of two industry groups: Health Care Equipment (code 3510) and Pharmaceuticals & Biotechnology (code 3520).

In Figure 1, we plot the cumulative return of the GEM3 World factor. This essentially represents the cap-weighted return (currency hedged) of the ACWI IMI. We also plot the cumulative active return of the two Health Care industry groups versus the ACWI IMI. What stands out is the steep rise and fall of the Pharmaceuticals & Biotechnology industry group. During the first two months of 2014, it outperformed the broad market by more than 800 bps. Since then, however, Pharmaceuticals & Biotechnology has seen a steep decline, although it is still slightly positive for the year.

Figure 1: Year-to-date performance of the GEM3 World factor and active performance of GICS-based industry groups of the ACWI IMI Health Care sector relative to the ACWI IMI, January 1, 2014 – April 11, 2014.




In Figure 2, we plot the cumulative active return of the three industry groups within the Information Technology sector (GICS code 45). These industry groups are: Software & Services (code 4510), Technology Hardware (code 4520) and Semiconductors (code 4530).

We see that Software & Services exhibited a similar pattern of behavior relative to Pharmaceuticals & Biotechnology; in both cases, the performance was very strong for the first two months of the year before suffering steep declines as we moved into March. Year-to-date, Software & Services has underperformed the broad equity market by almost 300 bps.

The Technology Hardware industry group has moved mostly sideways during 2014, now with a cumulative active return close to zero. By contrast, the Semiconductors industry group declined sharply the first week of January, but has climbed upward since then. At present, Semiconductors have outperformed the broad market by almost 500 bps, year-to-date.

Figure 2: Year-to-date active performance of GICS-based industry groups of the ACWI IMI IT sector relative to the ACWI IMI, January 1, 2014 – April 11, 2014.




Industry Group Performance Attribution Using GEM3

We now consider performance attribution for these industry groups relative to the ACWI IMI. We attribute active returns to the GEM3 factors and stock-specific contributions. We focus on Pharmaceuticals & Biotechnology and Software & Services, the two industry groups hit particularly hard.

In Figure 3, we see that the active performance of Pharmaceuticals & Biotechnology is mainly driven by GEM3 industry factors; their contribution rose until the end of February, and declined steadily since then. Style factor contributions were flat until mid-March, and have turned negative since then.

During the week of April 4 through April 11, stock-specific contributions fell 55 bps, mainly due to the decline of Pfizer, AbbVie, and Roche. In the same week, industry factors dragged down performance by 40 bps. At the same time, style factors contributed -30 bps, mainly because of the underperformance of the Momentum factor.

Figure 3: Year-to-date return attribution of the active returns of Pharmaceuticals & Biotechnology GICS industry group, relative to the ACWI IMI, January 1, 2014 – April 11, 2014.




In Figure 4, we turn to the Software & Services industry group. As with Pharmaceuticals & Biotechnology, the active performance was mainly driven by industry factors, which again showed a rise until late February and a steady decline since then. Style factor contributions were flat until mid-March, and have turned negative since then.

Specific contributions in this industry group were large, 3.5 percent, mainly due to large stock-specific returns from Facebook and Google in late January, and from Microsoft in mid-March.

During the week of April 4 through April 11, style factors appeared to drive the sell-off more than industry factors. For example, industry factors lost 55 bps, while style factors lost 88 bps, mainly due to the negative contributions of the Beta, Residual Volatility and Momentum factors. Stock-specific returns, on the other hand, added 1.5 percent, mainly due to Facebook and IBM.

Figure 4: Year-to-date return attribution of the active returns of Software & Services GICS industry group relative to the ACWI IMI, January 1, 2014 – April 11, 2014.



Which Industry and Style Factors Drove the Sell-Off?


In this study, we see that the GEM3 industry factors are the major drivers of underperformance in these two industry groups: Pharmaceuticals & Biotechnology and Software & Services. We now want to look deeper at the GEM3 industry factors driving the underperformance.

Under the Pharmaceuticals & Biotechnology industry group there are two corresponding GEM3 industry factors: 'Biotechnology' and 'Pharmaceuticals, Life Sciences.'

Under the Software & Services industry group there are two corresponding GEM3 industry factors: 'Internet Software & Services' and 'IT Services, Software.'

As Figure 5 shows, the four industry factors in question exhibited similar behavior recently. They started the year outperforming, in some cases modestly, with the GEM3 Biotechnology factor peaking at 11 percent in late February. From March onward, the industry factors started to decline, and now only the Pharmaceuticals industry factor has a positive year-to-date performance of roughly 3.5 percent.

Figure 5: Year-to-date return of GEM3 industry factors spanning the Software & Services and Pharmaceuticals & Biotechnology GICS industry groups, January 1, 2014 – April 11, 2014.




Now we turn to the GEM3 style factors. In Figure 6, we show the cumulative performance of four style factors: Beta, Growth, Momentum and Earnings Yield.

While Momentum started to underperform in early March, the Earnings Yield factor started to outperform at around the same time; this observation from GEM3 has not been widely observed by market commentators.

In the financial news, the recent sell-off episodes have been linked to the underperformance of growth and high beta stocks. We found that the Growth factor did show a pattern similar to that of Momentum, but on a more modest scale; namely, it rose in the first half of the period but started to decline in early March. Although the Beta factor had several days with large drawdowns during the same period, overall, it has declined less, which limited its potential contribution to portfolio returns.

Figure 6: Year-to-date return of select GEM3 style factors, January 1, 2014 – April 11, 2014.



Portfolio Exposures and Factor Returns

The effect of GEM3 factors on GICS industry groups depends on 1) exposures of constituent assets to the factors, and 2) returns of the factors. In Table 1 we show the exposure of the five GICS industry groups to the four GEM3 style factors, as of the end of February 2014.

Exposure to Beta was small and negative in all industry groups, except for Software & Services, where it reached 0.14. As events in March and April unfolded, Beta exposures became somewhat more positive, but because of the relatively flat return to the Beta factor in March and April, it did not have a large effect on the return of the industry group portfolios during that period.

Pharmaceuticals & Biotechnology and Software & Services had the largest positive exposures to the Momentum factor (0.40 and 0.39, respectively) and the largest negative exposure to the Earnings Yield factor (-0.45 and -0.39, respectively). These industry groups' positive exposure to the Momentum factor (which had negative returns) and negative exposure to the Earnings Yield factor (which had positive returns) combined to drive the negative contribution to return (from style factors) since March.

The exposure to the Growth factor was negligible, with the exception of the Software & Services and Semiconductors industry group (0.35 and 0.37, respectively), but the small returns to the Growth factor since March resulted in a small contribution.

Table 1: Style exposures of the industry groups, and their largest stocks, as of February 28, 2014.

Industry Group	Exposure as of February 28				Largest Stock
	Beta	Momentum	Earnings Yield	Growth	
Health Care Equipment	-0.29	0.21	-0.21	0.00	United Health
Pharmaceutical & Biotechnology	-0.06	0.40	-0.45	-0.04	Johnson & Johnson
Software & Services	0.14	0.39	-0.39	0.35	Google
Technology Hardware	-0.16	0.18	0.20	0.37	Apple
Semiconductors	0.00	-0.06	0.03	0.08	Samsung

In Table 2, we collected weekly returns to the World factor, as well as to the four style factors and four industry factors mentioned earlier. We also present standardized weekly returns (or z-scores), which account for the different volatilities of the factors, and allow a more apples-to-apples comparison of their performance.

The World and Beta factors had relatively large negative returns only in the second week of March and second week of April. The Momentum factor, on the other hand, declined five weeks out of six (although these declines were not particularly significant, since the largest negative z-score was -1.88 during the last week of March). In contrast, the Earnings Yield factor had a strongly positive performance during the last week of March and first week of April (z-score of 2.92 and 3.49, respectively).

During the last week of March, the Growth factor showed the opposite behavior, and realized one of the largest risk-adjusted drops (z-score of -2.57). This may be an indication that investors started to rotate from growth to value stocks during this period.

Finally, the four industry factors showed a decline during almost all weeks in the study period. The most significant losses occurred during the last week of March, which continued into the first week of April for the Internet Software & Services factor.

Table 2: Weekly factor returns, GEM3S model, with z-scores above '2' in absolute value highlighted.

Factor	Return (%)						Z-score					
	Week Ending						Week Ending					
	3/7	3/14	3/21	3/28	4/4	4/11	3/7	3/14	3/21	3/28	4/4	4/11
World	0.37	-2.60	0.94	0.81	1.15	-2.27	0.29	-1.96	0.70	0.61	0.85	-1.67
Beta	0.29	-0.76	0.09	0.22	0.14	-0.66	0.82	-2.13	0.24	0.63	0.39	-1.82
Momentum	-0.10	0.10	-0.13	-0.61	-0.14	-0.41	-0.31	0.31	-0.40	-1.88	-0.40	-1.11
Earnings Yield	0.18	-0.03	0.19	0.40	0.52	-0.02	1.34	-0.24	1.42	2.92	3.49	-0.10
Growth	-0.02	-0.02	0.00	-0.19	-0.07	-0.02	-0.24	-0.27	0.03	-2.57	-0.96	-0.27
Biotechnology	-3.38	0.55	-2.34	-4.66	-2.34	-0.54	-1.87	0.29	-1.24	-2.36	-1.07	-0.24
Pharmaceuticals, Life Sciences	-1.29	-0.03	0.05	-1.57	-0.44	-0.39	-2.06	-0.04	0.07	-2.34	-0.61	-0.52
Internet Software & Services	-0.02	-1.55	-0.52	-2.44	-3.37	-0.26	-0.02	-1.60	-0.53	-2.48	-3.21	-0.22
IT Services, Software	-0.61	-0.88	-0.14	-1.55	-0.80	-0.68	-1.29	-1.83	-0.29	-3.08	-1.46	-1.18

Conclusion

Recently, market observers noticed several rounds of sell-offs in information technology and health care stocks. The reason for these large drops remained largely unclear, especially given the backdrop of slowly but steadily improving economic data. Commentators also tried to attribute these losses to movements in common factors, and spoke of a possible sell-off in momentum, growth or high beta stocks.

In this Global Market Report, we looked at the performance of the GICS industry groups in the Health Care and Information Technology sectors since the beginning of 2014, and analyzed the drivers through the lens of the GEM3 model.

Financial news has highlighted declines in the health care and information technology sectors; however, the industry groups within these sectors were not uniform in their behavior during the recent sell-off period. For example: Software & Services and Pharmaceuticals & Biotechnology underperformed steeply, while Semiconductors have had a great year so far.

We found that this behavior was mainly driven by the performance of the four GEM3 industry factors spanning these GICS industry groups: 'Biotechnology,' 'Pharmaceuticals, Life Sciences,' 'Internet Software & Services' and 'IT Services, Software.'

Furthermore, we found that the most important negative style contributions to the decline since March 2014 came from the Momentum and Earnings Yield factors. We also found that the recent large drops in the Software & Services and Pharmaceuticals & Biotechnology industry groups were part of a broader decline that had started as early as the first week of March. The GEM3 model allowed us to look deeply at the factors driving this event, and understand what really happened in the recent "Tech Wreck."

Client Service Information is Available 24 Hours a Day

clientservice@msci.com

Americas

Americas	1.888.588.4567 (toll free)
Atlanta	+ 1.404.551.3212
Boston	+ 1.617.532.0920
Chicago	+ 1.312.675.0545
Monterrey	+ 52.81.1253.4020
New York	+ 1.212.804.3901
San Francisco	+ 1.415.836.8800
Sao Paulo	+ 55.11.3706.1360
Toronto	+ 1.416.628.1007

Europe, Middle East & Africa

Cape Town	+ 27.21.673.0100
Frankfurt	+ 49.69.133.859.00
Geneva	+ 41.22.817.9777
London	+ 44.20.7618.2222
Milan	+ 39.02.5849.0415
Paris	0800.91.59.17 (toll free)

Asia Pacific

China North	10800.852.1032 (toll free)
China South	10800.152.1032 (toll free)
Hong Kong	+ 852.2844.9333
Seoul	00798.8521.3392 (toll free)
Singapore	800.852.3749 (toll free)
Sydney	+ 61.2.9033.9333
Taipei	008.0112.7513 (toll free)
Tokyo	+ 81.3.5290.1555

Notice and Disclaimer

- This document and all of the information contained in it, including without limitation all text, data, graphs, charts (collectively, the "Information") is the property of MSCI Inc. or its subsidiaries (collectively, "MSCI"), or MSCI's licensors, direct or indirect suppliers or any third party involved in making or compiling any Information (collectively, with MSCI, the "Information Providers") and is provided for informational purposes only. The Information may not be reproduced or disseminated in whole or in part without prior written permission from MSCI.
- The Information may not be used to create derivative works or to verify or correct other data or information. For example (but without limitation), the Information may not be used to create indexes, databases, risk models, analytics, software, or in connection with the issuing, offering, sponsoring, managing or marketing of any securities, portfolios, financial products or other investment vehicles utilizing or based on, linked to, tracking or otherwise derived from the Information or any other MSCI data, information, products or services.
- The user of the Information assumes the entire risk of any use it may make or permit to be made of the Information. NONE OF THE INFORMATION PROVIDERS MAKES ANY EXPRESS OR IMPLIED WARRANTIES OR REPRESENTATIONS WITH RESPECT TO THE INFORMATION (OR THE RESULTS TO BE OBTAINED BY THE USE THEREOF), AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, EACH INFORMATION PROVIDER EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES (INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF ORIGINALITY, ACCURACY, TIMELINESS, NON-INFRINGEMENT, COMPLETENESS, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE) WITH RESPECT TO ANY OF THE INFORMATION.
- Without limiting any of the foregoing and to the maximum extent permitted by applicable law, in no event shall any Information Provider have any liability regarding any of the Information for any direct, indirect, special, punitive, consequential (including lost profits) or any other damages even if notified of the possibility of such damages. The foregoing shall not exclude or limit any liability that may not by applicable law be excluded or limited, including without limitation (as applicable), any liability for death or personal injury to the extent that such injury results from the negligence or willful default of itself, its servants, agents or sub-contractors.
- Information containing any historical information, data or analysis should not be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. Past performance does not guarantee future results.
- None of the Information constitutes an offer to sell (or a solicitation of an offer to buy), any security, financial product or other investment vehicle or any trading strategy.
- You cannot invest in an index. MSCI does not issue, sponsor, endorse, market, offer, review or otherwise express any opinion regarding any investment or financial product that may be based on or linked to the performance of any MSCI index.
- MSCI's subsidiaries Institutional Shareholder Services Inc. ("ISS") and MSCI ESG Research Inc. are Registered Investment Advisers under the Investment Advisers Act of 1940. Except with respect to any applicable products or services from ISS or MSCI ESG Research, neither MSCI nor any of its products or services recommends, endorses, approves or otherwise expresses any opinion regarding any issuer, securities, financial products or instruments or trading strategies and neither MSCI nor any of its products or services is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.
- The MSCI ESG Indexes use ratings and other data, analysis and information produced by MSCI ESG Research Inc. Issuers mentioned or included in any MSCI ESG Research materials may be a client of MSCI, ISS, or another MSCI subsidiary, or the parent of, or affiliated with, a client of MSCI, and may also purchase research or tools from MSCI ESG Research Inc. MSCI ESG Research materials, including materials utilized in any MSCI ESG Indexes or other products, have not been submitted to, nor received approval from, the United States Securities and Exchange Commission or any other regulatory body.
- Any use of or access to products, services or information of MSCI requires a license from MSCI. MSCI, Barra, RiskMetrics, IPD, FEA, InvestorForce, and other MSCI brands and product names are the trademarks, service marks, or registered trademarks of MSCI or its subsidiaries in the United States and other jurisdictions. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and Standard & Poor's. "Global Industry Classification Standard (GICS)" is a service mark of MSCI and Standard & Poor's.

About MSCI

MSCI Inc. is a leading provider of investment decision support tools to investors globally, including asset managers, banks, hedge funds and pension funds. MSCI products and services include indexes, portfolio risk and performance analytics, and governance tools.

The company's flagship product offerings are: the MSCI indexes with approximately USD 8 trillion estimated to be benchmarked to them on a worldwide basis¹; Barra multi-asset class factor models, portfolio risk and performance analytics; RiskMetrics multi-asset class market and credit risk analytics; IPD real estate information, indexes and analytics; MSCI ESG (environmental, social and governance) Research screening, analysis and ratings; ISS corporate governance research, data and outsourced proxy voting and reporting services; and FEA valuation models and risk management software for the energy and commodities markets. MSCI is headquartered in New York, with research and commercial offices around the world.

¹ As of September 30, 2013, as reported on January 31, 2014 by eVestment, Lipper and Bloomberg

Feb 2014